The first 2 families of proprietary molecules (AF122 and AF243) selected by Affichem are aimed at markets that have major and unsatisfied needs: acute myeloid leukemias, metastatic melanoma and refractory breast cancers and hearing loss. The third one is aiming cosmetics market (AF130). Affichem also targets the diagnostics market with the discovery of a breast cancer biomarker for the detection and monitoring of the therapeutic efficacy of anti-cancer drugs (AF300). This marker, intended for commercialization, but also for the optimization of internal clinical research, launches Affichem into the field of theranostics.
The proprietary molecules of Affichem are natural New Chemical Entities (NCE) discovered while studying the mechanism of action of Tamoxifen in INSERM lab of Dr Marc Poirot. These molecules are strong inducers of cell differentiation. Due to their effects, these molecules enable damaged cells or cells perturbed by a disease, a trauma or age, either to recover a normal activity or to be eliminated.
Depending on the subfamily to which they belong, these molecules induce cancer cells redifferentiation and death (AF122) or cause neuronal differentiation and the survival of neurons (AF243) or stimulate melanin production in skin (AF130).
Moreover, their production by chemical synthesis is simple and without the risk of biological contamination. AF243: a drug to restore hearing. AF243 induces neuron survival and neuronal differentiation. Its efficacy has been validated in vivo, on a robust model of chemically-induced deafness, designed to test cochlear implants.
The non-peptide nature of AF243 gives it a competitive advantage over the currently known neurotrophic factors. In addition, its synthesis by chemical means, not by biotechnological processes, guarantees its biological safety. The pharmacological properties of AF243 suggest that it may be used to treat other neurodegenerative diseases, in particular retinopathies that involve the same type of neurons as those of the auditory system.
They represent important potential markets currently lacking investment by the pharmaceutical industry.